Navigation Links
The National Plaintiff’s Law Firm of Baron and Budd Handling Granuflo Recall Lawsuits
Date:5/8/2013

Dallas, TX (PRWEB) May 08, 2013

The National Plaintiff’s Law Firm of Baron and Budd is now handling lawsuits pertaining to the recall of Granuflo, the brand name of a dialysate (http://www.fda.gov/medicaldevices/safety/listofrecalls/ucm309990.htm
). Dialysate is used when a patient undergoes dialysis, a long-term medical treatment used to treat kidney conditions. Granuflo has been known to allegedly cause various health issues including heart attack and stroke. The Granuflo lawyers at Baron and Budd are currently working to aid patients and families that have allegedly endured significant health issues after using Granuflo (IN RE: FRESENIUS GRANUFLO/NATURALYTE. DIALYSATE PRODUCTS LIABILITY LITIGATION. MDL No. 2428, Dist. Of Mass).

“It is Baron and Budd’s mission to uncover the facts that manufacturers don’t want their customers to know,” said Russell Budd, co-founder and managing shareholder of Baron and Budd. "When important research uncovers dangerous side effects, that research should immediately be made public."

According a New York Times article dated June 15, 2012, Fresenius Medical Care is the manufacturer of Granuflo and the world’s largest producer of products and services for kidney dialysis. More than one-third of the over 400,000 Americans who undergo dialysis treatments go to Fresenius clinics each year. (http://www.nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html?_r=0)

The New York Times also reported that the Federal Drug Administration (FDA) issued a Granuflo a recall on March 29, 2012 to change the drug’s prescribing instructions. The recall said that the use of Granuflo could potentially lead to significant heart problems in patients, such as low blood pressure and cardiac arrhythmia. However, Fresenius allegedly knew that the product could harm patients as early as November 2011, according to an internal company memo. (http://www.nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html?_r=1&;)

If you or someone you know has undergone dialysis with Granuflo treatments and experienced severe health complications, contact Baron and Budd’s Granuflo lawyers today at 1.866.855.4556 or email us at info (at) baronbudd (dot) com.

For more information about our Granuflo attorneys, visit Baron and Budd’s website here: http://baronandbudd.com/areas-of-practice/pharmaceuticals/granuflo-lawyer/.

For more than 35 years, Baron and Budd lawyers have been protecting the rights of people against negligent companies. The firm has an established track record of success when going up against large corporations, including pharmaceutical companies. Recently, our lawyers were involved in the litigation surrounding diabetes drug Avandia. Baron and Budd represented more than 7,000 patients allegedly harmed by Avandia use, and currently represents numerous states in lawsuits against manufacturer GlaxoSmithKline (In Re: Avandia Marketing, Sales Practices and Products Liability Litigation, MDL No. 1871, E.D. Pa.). In the 1990s, the firm was closely involved in the litigation surrounding then-popular diet drug Fen-Phen. The resulting settlement was valued at over $1.275 billion (In re Diet Drugs (Phentermine | Fenfluramine | Dexfenfluramine) Products Liability Litigation, Case No. 98- MDL No. 1203 (E.D. Pa.).

About Baron & Budd

The law firm of Baron & Budd, with offices in Dallas, Baton Rouge, Austin and Los Angeles, is a nationally recognized law firm with over 35 years of “Protecting What’s Right” for people, communities and businesses harmed by negligence. Baron & Budd’s size and resources enable the firm to take on large and complex cases. The firm represents individuals, governmental and business entities in areas as diverse as water contamination, Gulf oil spill, Qui Tam, California Proposition 65 violations, unsafe drugs and medical devices, Chinese drywall, deceptive advertising, consumer financial fraud, securities fraud and asbestos cancers such as mesothelioma.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10700127.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. National Transitions of Care Coalition to Host Regional Summit in Nashville
2. ZTL Linear LED Tube To Illuminate LIGHTFAIR® International 2013
3. National Quality Forum Testifies at U.S. House Ways and Means Health Subcommittee Hearing
4. Hub International to Offer Webinar on Preparing for Health Care Reform in 2014
5. New Video from the International Essential Tremor Foundation Addresses the Emotional and Psychosocial Aspects of Essential Tremor
6. Penn study shows national movement against non-medically indicated deliveries prior to 39 weeks
7. Grief and Mother’s Day: National Grief Expert's 10 Tips to Remember Mom with Peace
8. Nurse.com Releases New E-Book of Inspirational Stories in Honor of National Nurses Week 2013
9. Kamut International Announces Partnership with Professional Ironman Champion Linsey Corbin
10. Newport Board Group, a National Business Advisory Firm of CEOs Serving the Emerging Middle Market, Releases a Technology Roadmap for Private Companies
11. Contemporary Forums Celebrates National Nurses Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... The V Foundation for Cancer ... a Moment to Lose fundraising campaign. As the V Foundation’s boldest initiative to ... over cancer. The campaign aims to raise $200 million by 2020 and strategically ...
(Date:12/6/2016)... ... December 06, 2016 , ... Just in time for the holiday ... chocolate chip cookie recipe for Honeyville’s new Organic Quinoa Flour product for sale at ... in the near future. , “I think it’s wonderful that a growing number ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... November 25th, when SevenPoint2 released the much-anticipated HydroFX for Water®. This first-of-its-kind ... design. Featuring one of the world’s most powerful antioxidants, molecular hydrogen, HydroFX ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... recount of a powerful woman's story of sacrifice and enlightenment. , ... published author, Carolyn Fryer. Always looking for creative outlets, Carolyn gravitated toward writing ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... only authorized OSHA Training Institute Education Center headquartered in Northern California, has announced ... on providing occupational safety and health training to public sector employees. , “The ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Pa. , Dec. 5, 2016  Pennsylvania Physician ... Drug and Alcohol Programs Gary Tennis today ... drug, at Minnich,s Pharmacy in York ... order signed by Dr. Levine as a prescription to ... "It,s important to remember that any Pennsylvanian ...
(Date:12/5/2016)... India , December 5, 2016 According ... by Treatment modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free ... published by MarketsandMarkets, the market is projected to reach USD 779.8 ... a CAGR of 13.5% during the forecast period of 2016 to ... ...
(Date:12/5/2016)... Sanovas, Inc., a life science asset holding company ... wholly owned subsidiary, Intubation Science, Inc., and its LightSpeed Intubation ... http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... Sanovas, Inc. ... There are over 40 million Endotracheal Intubations performed annually ...
Breaking Medicine Technology: